- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2024 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
An Expert Discusses Nubeqa Side Effects Patients Should Know About
Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Long-term follow-up of Nubeqa for nonmetastatic castration-resistant prostate cancer showed that the drug was safe and effective in treating this patient population.
Long-term follow-up from the ARAMIS trial showed that Nubeqa (darolutamide) is not only efficacious in treating patients with nonmetastatic castration-resistant prostate cancer, but the drug also is tolerable, explained Dr. Neal Shore.
In a recent interview at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, Shore, US chief medical officer, Surgery and Oncology, GenesisCare USA, the medical director, Carolina Urologic Research Center, discussed Nubeqa-related side effects that patients may expect and should look out for when starting on the therapy.
READ MORE: Nubeqa Outperforms Xtandi, Erleada in Non-metastatic Castration-resistant Prostate Cancer
Nubeqa works by blocking androgens (male sex hormones) from binding to androgen receptors, and, in doing so, preventing cancer cells from surviving and reproducing.
Transcription
Well, you know, what, particularly with (Nubeqa), and you see this within the class of androgen receptor signaling inhibitors is you can have some more fatigue, you can get some occasional muscular-skeletal discomfort, and the occasional urinary tract infection (or) hot flush.
But in what we've seen in earlier studies, early phase 1 (and) 2 studies, is really a paucity of cognitive impairment. A paucity of depression that we've seen across the class of (androgen-receptor signaling) and particularly cognitive impairment, we haven't seen a high incidence of falls, we haven't seen a particular high incidence of hypertension or cardiovascular effects, and less than 1% incidence of grade 1/2-type rash.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content:
